Group 1 - The core point of the article is that Beihai Kangcheng-B (01228) announced a share placement to WuXi Biologics, leading to a significant increase in its stock price [1] - The company plans to issue 84.03 million new shares, representing approximately 14.12% of the enlarged issued share capital, at a price of HKD 2.38 per share, which is a discount of about 14.7% compared to the closing price of HKD 2.79 on February 13 [1] - The net proceeds from the placement are expected to reach HKD 199 million, with around 60% allocated for settling trade payables, approximately 28% for R&D expenses of existing product lines, and the remaining 12% for working capital and regulatory maintenance of commercialized products [1] Group 2 - Following the completion of the placement, WuXi Biologics' stake in Beihai Kangcheng will increase to approximately 16.27% [1]

Group 1 - The core viewpoint of the article highlights that Valiant Bio-B (09887) has seen a significant increase in stock price, rising over 6% following the announcement of its inclusion in the Hang Seng Composite Index [1] - As of the report, Valiant Bio-B's stock price is at 65.1 HKD with a trading volume of 18.6588 million HKD [1] - The inclusion in the Hang Seng Composite Index will take effect after the market closes on March 6, 2026, and will be effective from March 9, 2026, which may lead to adjustments in the Hong Kong Stock Connect investment scope [1] Group 2 - Valiant Bio-B has announced the successful administration of its drug, VILISEN™ (PD-L1/4-1BB bispecific antibody Opalizumab, LBL-024), to the first patient in a Phase Ib/II clinical trial for treating recurrent or metastatic triple-negative breast cancer [1] - The open-label, multicenter Phase Ib/II clinical study is led by Professor Yin Yongmei from Jiangsu Provincial People's Hospital and is being conducted across multiple hospitals nationwide [1] - The trial aims to evaluate the efficacy and safety of Opalizumab either as a monotherapy or in combination with albumin-bound paclitaxel for patients with recurrent or metastatic triple-negative breast cancer [1]

每经AI快讯，2月16日，中慧生物-B(02627.HK)涨16.12%，报59.8000港元，股价创历史新高，总市值 235.28亿港元。 ...

中慧生物-B（02627）发布公告，本公司H股已获选定并将纳入恒生综合指数成份股，自2026年3月9日 起生效。恒生综合指数作为全面的H股指标，涵盖在香港交易所主板上市的累计市值最高95%的公司， 并获指数基金、互惠基金及业绩评估系统的广泛应用。 董事会认为，本公司获纳入恒生综合指数成份股，反映资本市场对本公司业务表现及增长前景的认同。 董事会相信，此次纳入将有助于扩大本公司股东基础，提升H股的交易流通性，并进一步增强本公司的 声誉及品牌知名度。 董事会认为，本公司获纳入恒生综合指数成份股，反映资本市场对本公司业务表现及增长前景的认同。 董事会相信，此次纳入将有助于扩大本公司股东基础，提升H股的交易流通性，并进一步增强本公司的 声誉及品牌知名度。 责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 中慧生物-B（02627）发布公告，本公司H股已获选定并将纳入恒生综合指数成份股，自2026年3月9日 起生效。恒生综合指数作为全面的H股指标，涵盖在香港交易所主板上市的累计市值最高95%的公司， 并获指数基金、互惠基金及业绩评估系统的广泛应用。 责任编辑：卢昱君 热点栏目 自选股 ...

董事会认为，本公司获纳入恒生综合指数成份股，反映资本市场对本公司业务表现及增长前景的认同。 董事会相信，此次纳入将有助于扩大本公司股东基础，提升H股的交易流通性，并进一步增强本公司的 声誉及品牌知名度。 智通财经APP讯，中慧生物-B(02627)发布公告，本公司H股已获选定并将纳入恒生综合指数成份股，自 2026年3月9日起生效。恒生综合指数作为全面的H股指标，涵盖在香港交易所主板上市的累计市值最高 95%的公司，并获指数基金、互惠基金及业绩评估系统的广泛应用。 ...

Core Viewpoint - The approval of the IND application for CS2009 by the FDA marks a significant advancement in the global development of this innovative immunotherapy for advanced solid tumors [1][2] Group 1: Clinical Trial Progress - The Phase II clinical trial for CS2009 is actively enrolling participants in Australia and China, encompassing 15 monotherapy/combinatorial regimens and 9 solid tumor indications, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), triple-negative breast cancer (TNBC), extensive-stage small cell lung cancer (ES-SCLC), and platinum-resistant ovarian cancer (PROC) [1] - Preliminary data from the Phase I clinical study of CS2009 has shown good safety and tolerability, with positive anti-tumor activity results expected to be presented at the upcoming ASCO and ESMO meetings [1] Group 2: Company Leadership Insights - The CEO and President of R&D at the company expressed satisfaction with the efficient advancement of the global Phase II clinical trial and the FDA's approval, highlighting the positive communication and collaboration with the FDA [2] - The approval was based on the FDA's recognition of the good safety and anti-tumor activity demonstrated in the Phase I trial, confirming the research plan for the Phase II trial, including dose optimization strategies and other core elements [2]

Core Viewpoint - The approval of the IND application for CS2009 by the FDA marks a significant advancement in the global development of this innovative immunotherapy for advanced solid tumors [1][2] Group 1: Clinical Trial Details - CS2009 is undergoing a Phase II clinical trial for advanced solid tumors, with active enrollment in Australia and China [1] - The trial includes 15 monotherapy/combo therapy regimens and 9 solid tumor indications, such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), triple-negative breast cancer (TNBC), extensive-stage small cell lung cancer (ES-SCLC), and platinum-resistant ovarian cancer (PROC) [1] - Preliminary data from the Phase I clinical study has shown good safety and tolerability, with positive anti-tumor activity results expected to be presented at the upcoming ASCO and ESMO meetings [1] Group 2: Company Statements - The CEO of the company expressed satisfaction with the efficient progress of the Phase II clinical trial and the FDA's approval, highlighting the positive communication between the company and the FDA [2] - The approval was based on the FDA's recognition of the good safety and anti-tumor activity demonstrated in the Phase I trial, confirming the study design for the Phase II trial [2] - The company is committed to advancing the global clinical development of CS2009 and anticipates sharing more positive data and research progress soon [2]

Group 1 - The core announcement is that Beihai Kangcheng (stock code: 1228) plans to raise approximately HKD 200 million through the issuance of new shares, specifically 84,033,613 shares at a subscription price of HKD 2.38, which represents a discount of about 14.7% compared to the previous closing price of HKD 2.79 [1][1][1] - The funds raised will be allocated for operational capital for commercialized products, research and development expenses for existing product lines, and settling trade payables of the group [1][1][1] - After the issuance, the new shares will represent approximately 16.4% of the existing issued share capital and about 14.1% of the enlarged share capital [1][1][1] Group 2 - Beihai Kangcheng is focused on the biopharmaceutical sector, indicating its strategic direction and market positioning [1][1][1] - The issuance is conducted under a general authorization granted by the shareholders' meeting, with completion expected on the fifth business day after all conditions of the subscription agreement are met [1][1][1]

撰文丨王聪 编辑丨王多鱼 排版丨水成文 溶瘤病毒 （ Oncolytic Viruse， OV） 是癌症治疗中一种很有前景的疗法。这些具有复制能力的病毒在肿瘤细胞中的优先复制和溶瘤作用，以及溶瘤后激活的免 疫反应，被认为是溶瘤病毒发挥抗肿瘤作用的主要原因。基于单纯疱疹病毒 （HSV） 的首个获美国 FDA 批准的溶瘤病毒疗法 Imlygic 瘤内注射治疗黑色素瘤已 取得了显著成功。 2023 年 10 月， Alexander L. Ling 等人在 Nature 期刊发表论文 【1】 ，报告了一项 first in human 的 1 期临床试验的安全性数据，41 名 复发性胶质母细胞 瘤 （rGBM） 患者接受了基于 单纯疱疹病毒 1 型的溶瘤病毒 （ oHSV ） 的治疗，该溶瘤病毒经过精心设计改造，其 仅在胶质母细胞瘤细胞内选择性复制，同 时不损害健康脑组织。这种肿瘤趋向性的溶瘤病毒利用了癌细胞的弱点：一旦感染，它就会劫持癌细胞的机制来自我复制，从而导致受感染癌细胞的死亡。该溶 瘤病毒不仅仅是癌细胞杀伤剂，它还能引发免疫原性级联反应，将免疫系统的多种成分招募到肿瘤中。结果显示， 瘤内注射 oHSV 治 ...

同一报道显示，康乃德于2026年2月初完成2500万美元A轮融资，由启明创投领投，北极光创投等机构 跟投，预计资金将用于加速创新药物管线的开发，包括CBP-307、CBP-174等临床阶段项目。 机构观点 经济观察网2026年2月12日分析指出，尽管近期股价波动显著（2月5日至11日区间振幅达23.61%），但 机构评级维持强力买入建议，多家机构关注其T细胞调节平台的长期潜力。 经济观察网 康乃德生物近期在研发和融资方面取得进展，其核心药物CBP-307即将进入II期临床试验， 并完成2500万美元A轮融资。 公司项目推进 根据医管攻略2026年2月4日的报道，康乃德的主要候选药物CBP-307（用于治疗多发性硬化症、炎症性 肠病等自身免疫疾病）已完成I期临床试验，并即将进入II期临床试验阶段，这是公司研发管线的关键进 展。 资金动向 以上内容基于公开资料整理，不构成投资建议。 ...